Principles, Indications, and Techniques of Radiation Therapy of Lymphomas

The Lymphomas

Volumn , Issue , 2006, Pages 203-224

  Yahalom, Joachim ^a,b,c,d  

^a Lymphoma Disease Management Team   (United States)

^b Department of Radiation Oncology ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149338326     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0081-9.50016-9     Document Type: Chapter

References (116)

1. Hoppe RT, et al., NCCN physician guidelines: Hodgkin disease 2005 vol. 1. National Comprehensive Cancer Network. Available at: www.nccn.org. Accessed Sept. 2005.
2. V Diehl, RK Thomas and D Re (2004) Part II: Hodgkin's lymphoma—diagnosis and treatment. Lancet Oncol 5 19-26.
3. PJ Schlembach, RB Wilder, D Jones, et al. (2002) Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 8 377-383.
4. J Yahalom and P Mauch (2002) The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 13(Suppl 1), 79-83.
5. AK Ng, MP Bernardo, E Weller, et al. (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 2101-2108.
6. AK Ng and PM Mauch (2002) Controversies in early-stage Hodgkin's disease. Oncology (Huntingt) 16 588-595. 598; discussion 600, 605, 609–18
7. OW Press, M LeBlanc, AS Lichter, et al. (2001) Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19 4238-4244.
8. M Sieber, J Franklin, H Tesch, et al. (2002) Two cycles ABVD plus extended field radiotherapy is superior to radiothearpy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7. Blood 100 Abstract 341.
9. P Carde, E Noordijk and A Hagenbeek (1997) Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I—II Hodgkin's disease: The EORTC-GPMC H7F randomized trial. Proc ASCO 16 13.
10. A Hagenbeek, H Eghbali, C Ferme, et al. (2000) Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I—II Hodgkin's disease: preliminary results of the EORTC-GELA H9-F randomized trial in 543 patients. Blood 96 Abstract 575.
11. G Bonadonna, V Bonfante, S Viviani, et al. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22 2835-2841.
12. A Engert, P Schiller, A Josting, et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 3601-3608.
13. C Ferme, H Eghbali, A Hagenbeek, et al. (2000) MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I—II Hodgkin's disease: comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood 96 Abstract 576.
14. M Loeffler, V Diehl, M Pfreundschuh, et al. (1997) Dose—response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 15 2275-2287.
15. V Diehl, C Brillant, A Engert, et al. (2004) Reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: interim analysis of the HD 10 trial of the GHSG. Blood 104 Abstract 1307.
16. V Diehl, C Brillant, A Engert, et al. (2004) Intensification of chemotherapy and concomitant reduction of radiotherapy dose in intermediate stage Hodgkin's lymphoma: results of the fourth interim analysis of the HD 11 trial of the GHSG. Blood 104 Abstract 1308.
17. VT DeVita Jr (2003) Hodgkin's disease—clinical trials and travails. N Engl J Med 348 2375-2376.
18. DL Longo (2003) Radiation therapy in the treatment of Hodgkin's disease—do you see what I see? J Natl Cancer Inst 95 928-929.
19. GP Biti, G Cimino, C Cartoni, et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I—IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10 378-382.
20. DL Longo, E Glatstein, PL Duffey, et al. (1991) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol 9 906-917.
21. GP Canellos, JR Anderson, KJ Propert, et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 1478-1484.
22. P Carde, A Hagenbeek, M Hayat, et al. (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11 2258-2272.
23. JB Nachman, R Sposto, P Herzog, et al. (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 3765-3771.
24. S Laskar, T Gupta, S Vimal, et al. (2004) Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22 62-68.
25. R Meyer, M Gospodarowicz, JM Connors, et al. (2003) A randomized phase III comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: The HD-6 rial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative). Blood 102 Abstract 81.
26. V Diehl, H Stein, M Hummel, et al. (2003) Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) 225-247.
27. DJ Straus, CS Portlock, J Qin, et al. (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104 3483-3489.
28. LR Prosnitz, JJ Wu and J Yahalom (1996) The case for adjuvant radiation therapy in advanced Hodgkin's disease. Cancer Invest 14 361-370.
29. J Yahalom, J Ryu, DJ Straus, et al. (1991) Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 9 2193-2201.
30. DM Brizel, EP Winer, LR Prosnitz, et al. (1990) Improved survival in advanced Hodgkin's disease with the use of combined modality therapy [see comments]. Int J Radiat Oncol Biol Phys 19 535-542.
31. C Fabian, C Mansfield, S Dahlberg, et al. (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. Ann Intern Med 120 903-912.
32. M Loeffler, O Brosteanu, D Hasenclever, et al. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group [see comments]. J Clin Oncol 16 818-829.
33. BM Aleman, JM Raemaekers, U Tirelli, et al. (2003) Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 2396-2406.
34. DB Duggan, GR Petroni, JL Johnson, et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 607-614.
35. SJ Horning, RT Hoppe, S Breslin, et al. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20 630-637.
36. T Chisesi, M Federico, A Levis, et al. (2002) ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol 13(Suppl 1), 102-106.
37. JC Poen, RT Hoppe and SJ Horning (1996) High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival [see comments]. Int J Radiat Oncol Biol Phys 36 3-12.
38. J Yahalom, SC Gulati, M Toia, et al. (1993) Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11 1062-1070.
39. CH Moskowitz, SD Nimer, AD Zelenetz, et al. (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97 616-623.
40. CH Moskowitz, T Kewalramani, SD Nimer, et al. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124 645-652.
41. AD Zelenetz (2004) NCCN Physician Guidelines: Non-Hodgkin Lymphoma. Nat Comp Cancer Net 2(4), 286-294. Available at: www.nccn.org
42. MP Mac Manus and RT Hoppe (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14 1282-1290.
43. B Vaughan Hudson, G Vaughan Hudson, KA MacLennan, et al. (1994) Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69 1088-1093.
44. SB Sutcliffe, MK Gospodarowicz, RS Bush, et al. (1985) Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol 4 211-223.
45. RB Wilder, D Jones, SL Tucker, et al. (2001) Long-term results with radiotherapy for Stage I—II follicular lymphomas. Int J Radiat Oncol Biol Phys 51 1219-1227.
46. RS Bush, M Gospodarowicz, J Sturgeon, et al. (1977) Radiation therapy of localized non-Hodgkin's lymphoma. Cancer Treat Rep 61 1129-1136.
47. Z Fuks and H Kaplan (1973) Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology 108 675-679.
48. NI Nissen, J Ersboll, HS Hansen, et al. (1983) A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I—II non-Hodgkin's lymphomas. Cancer 52 1-7.
49. J Yahalom, G Varsos, Z Fuks, et al. (1993) Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71 2342-2350.
50. J Yahalom (2001) Radiation therapy for stage III follicular lymphoma—often ignored, but still effective. Int J Radiat Oncol Biol Phys 49 1-2.
51. SB Paryani, RT Hoppe, RS Cox, et al. (1984) The role of radiation therapy in the management of stage III follicular lymphomas. J Clin Oncol 2 841-848.
52. AD Murtha, BA Rupnow, J Hansosn, et al. (2001) Long-term followup of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys 49 3-15.
53. JP Jacobs, KJ Murray, CJ Schultz, et al. (1993) Central lymphatic irradiation for stage III nodular malignant lymphoma: longterm results. J Clin Oncol 11 233-238.
54. NP Mendenhall and JW Lynch Jr (1995) The low-grade lymphomas. Semin Radiat Oncol 5 254-266.
55. CS Ha, F Cabanillas, MS Lee, et al. (1997) Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I—III follicular lymphoma: a preliminary report. Clin Cancer Res 3 215-219.
56. A Aviles, JC Diaz-Maqueo, E Sanchez, et al. (1991) Long-term results in patients with low-grade nodular non-Hodgkin's lymphoma. A randomized trial comparing chemotherapy plus radiotherapy with chemotherapy alone. Acta Oncol 30 329-333.
57. F Bertoni, A Conconi, C Capella, et al. (2002) Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 99 2541-2544.
58. RI Fisher, S Dahlberg, BN Nathwani, et al. (1995) A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid Bcell subcategories): a Southwest Oncology Group study. Blood 85 1075-1082.
59. B Coiffier and G Salles (1997) Does surgery belong to medical history for gastric lymphomas? Ann Oncol 8 419-421.
60. AC Wotherspoon, C Doglioni and PG Isaacson (1992) Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): a multifocal disease. Histopathology 20 29-34.
61. NR Schechter, CS Portlock and J Yahalom (1998) Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16 1916-1921.
62. J Yahalom, CSP Portlock, M Gonzales, et al. (2002) H. pyloriindependent MALT lymphoma of the stomach: excellent outcome with radiation alone. Blood 100 160a.
63. RW Tsang, MK Gospodarowicz, M Pintilie, et al. (2001) Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 50 1258-1264.
64. CY Fung, ML Grossbard, RM Linggood, et al. (1999) Mucosa-associated lymphoid tissue lymphoma of the stomach: longterm outcome after local treatment. Cancer 85 9-17.
65. S Hitchcock, AK Ng, DC Fisher, et al. (2002) Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 52 1058-1066.
66. MK Gospodarowicz, M Pintilie, R Tsang, et al. (2000) Primary gastric lymphoma: brief overview of the recent Princess Margaret Hospital experience. Recent Results Cancer Res 156 108-115.
67. J Yahalom (2001) MALT lymphomas: a radiation oncology viewpoint. Ann Hematol 80 B100-B105.
68. C Della Bianca, M Hunt, E Furhang, et al. (2005) Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys 62 745-751.
69. RL Haas, P Poortmans, D de Jong, et al. (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21 2474-2480.
70. RL Haas and T Girinsky (2003) HOVON 47/EORTC 20013: chlorambucil vs 2 × 2Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients. Ann Hematol 82 458-462.
71. T Girinsky, D Guillot-Vals, S Koscielny, et al. (2001) A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 51 148-155.
72. HA Leitch, RD Gascoyne, M Chhanabhai, et al. (2003) Limited-stage mantle-cell lymphoma. Ann Oncol 14 1555-1561.
73. J Yahalom (1999) Radiation therapy in the treatment of lymphoma. Curr Opin Oncol 11 370-374.
74. SH Levitt, CK Lee, CD Bloomfield, et al. (1985) The role of radiation therapy in the treatment of early stage large cell lymphoma. Hematol Oncol 3 33-37.
75. DE Hallahan, R Farah, EE Vokes, et al. (1989) The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone. Int J Radiat Oncol Biol Phys 17 767-771.
76. P Carde, JM Burgers, M van Glabbeke, et al. (1984) Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975–1980 EORTC controlled lymphoma trial. Radiother Oncol 2 301-312.
77. S Monfardini, A Banfi, G Bonadonna, et al. (1980) Improved five year survival after combined radiotherapy-chemotherapy for stage I—II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 6 125-134.
78. DL Longo, E Glatstein, PL Duffey, et al. (1989) Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 7 1295-1302.
79. TN Shenkier, N Voss, R Fairey, et al. (2002) Brief chemotherapy and involved-region irradiation for limited-stage diffuse largecell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20 197-204.
80. MS Kaminski, CN Coleman, TV Colby, et al. (1986) Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 104 747-756.
81. SE Jones, TP Miller and JM Connors (1989) Long-term follow-up and analysis for prognostic factors for patients with limitedstage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7 1186-1191.
82. DA Stewart, JM Vose, DD Weisenburger, et al. (1995) The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6 263-266.
83. DL Longo (1989) Combined modality therapy for localized aggressive lymphoma: enough or too much? J Clin Oncol 7 1179-1181.
84. F Cabanillas, GP Bodey and EJ Freireich (1980) Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 46 2356-2359.
85. TP Miller and SE Jones (1983) Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 62 413-418.
86. TP Miller (2004) The limits of limited stage lymphoma. J Clin Oncol 22 2982-2984.
87. SJ Horning, E Weller, K Kim, et al. (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22 3032-3038.
88. TP Miller, S Dahlberg, JR Cassady, et al. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 21-26.
89. RI Fisher, TP Miller and OA O'Connor (2004) Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program) 221-236.
90. SS Kamath, RB Marcus Jr, JW Lynch, et al. (1999) The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 44 563-568.
91. I Roy and J Yahalom (2001) Excellent local control with involvedfield radiotherapy following CHOP chemotherapy: analysis of 145 patients with early-stage intermediate-grade non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 51 562a-563a.
92. RB Wilder, SL Tucker, CS Ha, et al. (2001) Dose–response analysis for radiotherapy delivered to patients with intermediategrade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 49 17-22.
93. PJ Schlembach, RB Wilder, SL Tucker, et al. (2000) Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III—IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 48 1107-1110.
94. MA Shipp, MM Klatt, B Yeap, et al. (1989) Patterns of relapse in large-cell lymphoma patients with bulk disease. implications for the use of adjuvant radiation therapy. J Clin Oncol 7 613-618.
95. A Aviles, S Delgado, MJ Nambo, et al. (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30 799-803.
96. AJ Ferreri, S Dell'Oro, M Reni, et al. (2000) Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III—IV diffuse large B cell lymphomas. Oncology 58 219-226.
97. L Fouillard, JP Laporte, M Labopin, et al. (1998) Autologous stemcell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation—results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 16 2803-2816.
98. A Aviles, R Fernandezb, F Perez, et al. (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 45 1385-1389.
99. A Aviles, EL Garcia, R Fernandez, et al. (2002) Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy. Ann Hematol 81 368-373.
100. PL Zinzani, M Martelli, M Bertini, et al. (2002) Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 87 1258-1264.
101. G Todeschini, S Secchi, E Morra, et al. (2004) Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 90 372-376.
102. HS Kaplan and SA Rosenberg (1966) The treatment of Hodgkin's disease. Med Clin North Am 50 1591-1610.
103. KA Goodman, S Toner, M Hunt, et al. (2005) Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62 198-206.
104. M Andre, N Mounier, X Leleu, et al. (2004) Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 103 1222-1228.
105. LB Travis, M Gospodarowicz, RE Curtis, et al. (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94 182-192.
106. LB Travis, RE Curtis, B Glimelius, et al. (1993) Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85 1932-1937.
107. GM Dores, C Metayer, RE Curtis, et al. (2002) Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20 3484-3494.
108. FE van Leeuwen, WJ Klokman, M Stovall, et al. (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 971-980.
109. LB Travis, D Hill, GM Dores, et al. (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's disease. JAMA 289.
110. J Yahalom (2003) Breast cancer after Hodgkin disease: hope for a safer cure. JAMA 290 529-531.
111. S Bhatia, LL Robison, O Oberlin, et al. (1996) Breast cancer and other second neoplasms after childhood Hodgkin's disease [see comments]. N Engl J Med 334 745-751.
112. R Doria, T Holford, LR Farber, et al. (1995) Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 13 2016-2022.
113. E Salloum, R Doria, W Schubert, et al. (1996) Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14 2435-2443.
114. E Salloum, LT Tanoue, FJ Wackers, et al. (1999) Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Cancer Invest 17 171-180.
115. GM Chronowski, RB Wilder, SL Tucker, et al. (2003) Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 55 36-43.
116. SL Hancock, MA Tucker and RT Hoppe (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270 1949-1955.